scispace - formally typeset
Search or ask a question
Topic

Psychotropic drug

About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: Medication‐related risk communication is a complex clinical phenomenon dictated by patients’ prior experiences and the pharmacists’ practice environment and extending the evidence base in this therapeutic area and refining clinical resources are key steps towards optimising patient medication safety.
Abstract: Background A core role of the pharmacist is to ensure safe and effective medication use. Therapeutic classes that impair alertness (e.g. sedatives or hypnotics) can pose safety concerns for the consumer when undertaking activities requiring psychomotor vigilance (e.g. driving). Objective To explore pharmacists' perceptions and communication strategy of the risks related to alertness impairing medications in clinical practice. Methods In-depth semi-structured interviews explored community pharmacists' perceptions of medication-related risks, current medication provision and the feasibility of new practice tools. Interviews were digitally recorded, transcribed verbatim and analysed using Framework Analysis to identify emergent themes. A Psychometric Risk Perception Questionnaire was also used to evaluate pharmacists' perceptions across 7 common psychotropic drug classes. Results Synthesis of the qualitative dataset of 30 pharmacist interviews revealed three key themes: ‘ Safety and Consequences of AIMs ', ‘ Factors that Influence Risk Communication ' and ‘ Refining Risk Communication '. Participating pharmacists were generally aware of the therapeutic classes associated with medication-related risks but were concerned about patients' level of understanding. Counselling approaches were largely dictated by perceived patient interest/experience with a medication. Concerns were centred on inter-individual pharmacokinetic differences, which could make the precise risk assignment difficult. Pharmacists also highlighted workflow limitations and the need to bring patients' attention to these resources during the clinical interaction to maximise impact. Conclusions Medication-related risk communication is a complex clinical phenomenon dictated by patients' prior experiences and the pharmacists' practice environment. Extending the evidence base in this therapeutic area and refining clinical resources are key steps towards optimising patient medication safety.

11 citations

Journal Article
TL;DR: Ad Advent of newer antipsychotic agents like olanzapine , risperidone and quetiapine has led to major changes in drug usage pattern in psychiatry, besides other considerations related to disease, patients, drugss and physician.
Abstract: Schizophrenia is a chronic debilitating major psychiatric disorder which may require life long treatment. Treatment of such patients at an early stage may prevent loss of morbidity, mortality and productivity. Till date, pharmacotherapy remains the cornerstone of treatment in such patients . Serendipitous discovery of chlorpromazine and lithium in the fifties brought about a revolution in the field of psychopharmacology. Although highly efficacious, the side-effects (Kane, 1987) produced by these older conventional drugs were distressing leading to an active search for better agents. Advent of newer antipsychotic agents like olanzapine , risperidone and quetiapine has led to major changes in drug usage pattern in psychiatry,besides other considerations related to disease,patients,drugs and physician.

11 citations

Journal ArticleDOI
TL;DR: For both males and females, illicit drug use was associated with psychotherapeutic medicine use, although the relationship was stronger among males than among females, and help‐seeking was strongly associated with prescription psychiatric symptoms among both genders.
Abstract: It has been shown that women are more likely than men to have used prescription psychotherapeutic medicines. Gender differences in the determinants of such use have also been identified. In an earlier study of adult household residents aged 18-44, we found that antecedent illicit drug use was associated with prescribed psychotherapeutic medicine use, independent of psychiatric symptoms. In this study, we explore these predictive relationships separately for males and females. For both males (n = 604) and females (n = 933) illicit drug use was associated with psychotherapeutic medicine use, although the relationship was stronger among males. Psychiatric symptoms did not account for this relationship for either gender. Among males, symptoms and illicit drug use each increased the likelihood of psychotherapeutic medicine use. Among females, no additional likelihood of psychotherapeutic medicine use over and above that for illicit drug use resulted when psychiatric symptoms were also present. Help-seeking was strongly associated with prescription psychotherapeutic medicine use among both genders.

11 citations

Journal ArticleDOI
TL;DR: Bupropion hydrochloride is a psychotropic drug with significant antidepressant effects through the inhibition of re-uptake of norepinephrine and it is shown that this drug acts as a ‘spatially aggregating agent’ to MDMA.
Abstract: Auteur(s) : Cristina GOMEZ-FERNANDEZ1 crisgomezfernandez@hotmail.com, Pedro HERRANZ PINTO1, Beatriz CASADO VERRIER1, Elena SENDAGORTA CUDOS1, Maria Jose BEATO-MERINO2, Mariano CASADO JIMENEZ1 1 University Hospital La Paz, Department of Dermatology, Paseo de la Castellana, 261, 28046. Madrid, Spain 2 University Hospital La Paz, Department of Pathology, Madrid, Spain Bupropion hydrochloride is a psychotropic drug with significant antidepressant effects through the inhibition of re-uptake of norepinephrine [...]

11 citations

Journal ArticleDOI
TL;DR: Asian groups received less potentially beneficial symptomatic treatments, and Asian and Black groups were prescribed antipsychotic drugs for longer than White ethnic groups, which may indicate care inequalities.
Abstract: Purpose To test hypotheses that minority ethnic people with dementia in the UK receive fewer anti-dementia drugs and more psychotropic and anticholinergic drugs associated with harms. Patients and methods We analyzed UK primary care electronic health records from The Health Improvement Network (THIN) database (2014-2016), comparing psychotropic drug prescribing initiation and duration between people with dementia from White, Black, and Asian ethnic groups. We repeated analyses in people (aged 50+) without dementia, to explore whether any differences found reflected prescribing patterns in the general older population, or were specific to dementia. Results We included 53,718 people with and 1,648,889 people without dementia. Among people with dementia, compared to White ethnic groups, Asian people were less likely to be prescribed anti-dementia drugs when they were potentially indicated (adjusted prevalence rate ratio 0.86 (95% Confidence Interval 0.76-0.98)), and received them for on average 15 days/year less. Compared to White groups, Asian and Black individuals with dementia were no more likely to take an antipsychotic drug, but those that had were prescribed them for 17 and 27 days/year more, respectively (190.8 (179.6-199.1) and 200.7 (191.1-206.5) days). Black people were less likely to be prescribed anxiolytics/hypnotics (0.60 (0.44-0.8)), but the duration these drugs were prescribed was similar across ethnic groups. Asian people were more likely to be prescribed anticholinergic drugs (1.43 (1.19-1.73)), in analyses unadjusted for cardiovascular comorbidities. Among people without dementia, those in the Asian and Black ethnic groups were less likely to be prescribed psychotropic drugs, relative to people from White groups. Conclusion Among people with dementia, Asian groups received less potentially beneficial symptomatic treatments, and Asian and Black groups were prescribed antipsychotic drugs for longer than White ethnic groups. Our findings may indicate care inequalities.

11 citations


Network Information
Related Topics (5)
Schizophrenia
38.2K papers, 1.6M citations
86% related
Anxiety disorder
17.6K papers, 1.3M citations
86% related
Comorbidity
26.8K papers, 1.4M citations
82% related
Anxiety
141.1K papers, 4.7M citations
81% related
Mental health
183.7K papers, 4.3M citations
81% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
202332
202268
202175
202058
201960
201876